VMD Launches Digital Pharmacovigilance Reporting Platform for Animal Medicines Industry
核心洞察
The UK Veterinary Medicines Directorate (搜索) launched a new digital pharmacovigilance reporting service for Marketing Authorisation Holders on 10 July 2026.
The platform consolidates multiple submission types including Benefit-Risk Submission Reports, Pharmacovigilance Sales Submissions, signal notifications, and XML adverse event files into a single system.
Key features include submission status tracking, exportable logs, in-system validation, and a built-in product dictionary for streamlined compliance.
The Veterinary Medicines Directorate (搜索) (VMD) has launched a new digital platform designed to streamline pharmacovigilance reporting for the animal medicines industry. The VMD Industry Pharmacovigilance Reporting Service went live on 10 July 2026, offering Marketing Authorisation Holders (MAHs) a unified system for submitting a range of safety and compliance documents.
The launch follows the earlier release of the VMD's Adverse Event Reporting Service on 20 May 2026, which serves animal owners, veterinary professionals, and Suitably Qualified Persons.
A Unified Platform for Multiple Submission Types
The new service consolidates several previously separate reporting workflows into a single digital platform. MAHs can now submit Benefit-Risk Submission Reports (BRSRs), Pharmacovigilance Sales Submissions (PSSs), dose factor justifications, signal notifications, and XML adverse event files through one interface.
The platform includes a built-in product dictionary that allows straightforward visualisation and selection of product groups and related product information. Additional features include submission status tracking, exportable logs, and in-system validation, all designed to help MAHs fulfil their legislative pharmacovigilance requirements more efficiently.
Beta Release and Feedback Mechanism
The VMD has released the service as an optional beta version, with continued testing and improvements planned. MAHs are encouraged to use the feedback function within the service to share their experiences, which the VMD will use to guide further enhancements. Additional functionality is already planned for rollout over the coming year.
MAHs who prefer to continue using the existing Veterinary Medicines Digital Service (VMDS) secure messaging service or the VMDS adverse events reporting system may do so, as the new platform is not mandatory at this stage.
Registration and Access
The VMD Industry Pharmacovigilance Reporting Service is for business use only and is not available to pet owners or members of the public. Eligible users include holders of marketing authorisations, animal test certificates, veterinary homeopathic registrations, and autogenous vaccine authorisations.
Registration requires providing a named person for the service, company details, and the number of licences needed. The VMD will verify that it is appropriate for the company to use the service and that the applicant is a legitimate representative. Consultants and agents cannot register independently unless already registered for the Veterinary Medicines Digital Service; they must be invited by a company to join that company's account.
The service is hosted by Ennov on behalf of the Veterinary Medicines Directorate (搜索) and uses a strictly necessary cookie for session management. Full guidance on using the service is provided within the platform itself, with technical support available via PHVReportingService@vmd.gov.uk.